Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Tyler Van Buren has maintained a Buy rating on ORKA stock, citing strong clinical data for ORKA-001 in psoriasis, which showed a 64% PASI 100 response. Oruka's robust financial position, with $1.2 billion in cash, supports the development of ORKA-001 without immediate financing needs. Upcoming Phase IIa data and the Phase IIb EVERLAST-B readout in 2027 are expected to further validate its potential, which is estimated to be multi-billion-dollar. H.C. Wainwright also reiterated a Buy rating with a $120 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments